{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:36:26Z","timestamp":1793637386612,"version":"4.5.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>New daily persistent headache (NDPH) is a rare headache disorder that often resembles chronic migraine (CM) phenotypically, but unlike CM is daily from onset. Several calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) have been proven to be effective in CM. It is not known whether CGRP mAbs are effective in NDPH. We sought to assess the efficacy, tolerability, and safety of CGRP mAbs in NDPH and compare their effect in NDPH to CM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We performed an observational study using prospectively collected data in consecutive patients treated with CGRP mAbs in three groups: Group 1 included patients with NDPH with migraine features; Group 2 included patients with CM with daily headache; and Group 3 patients with non-daily CM. Given the observational nature of the study, propensity score matching was used in an attempt to balance the three groups on baseline factors to make them comparable. The majority of patients were treated with erenumab while the remainder received galcanezumab. Patients completed a headache diary and disability questionnaires at baseline and 12-week follow-up, with the primary endpoint being the proportion who achieved a reduction of at least 30% in monthly moderate-to-severe headache days (MSHD) compared between the three groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 48 patients with NDPH, 101 with daily-CM, and 68 with non-daily-CM were included. From baseline to week 12, 11\/47 (23%) of patients with NDPH had a\u2009\u2265\u200930% improvement in MSHD, compared to 46\/99 (46%) in daily CM (OR 2.02, 95% CI 0.82\u20134.97, <jats:italic>p<\/jats:italic>\u2009=\u20090.125), and 51\/61 (84%) in non-daily-CM (OR 4.41, 95% CI 1.17\u201316.6, <jats:italic>p<\/jats:italic>\u2009=\u20090.028). Only 5\/47 (11%) of patients with NDPH had a\u2009\u2265\u200930% improvement in monthly headache days, and 24\/44 (54%) reported an overall subjective improvement of\u2009\u2265\u200930%. Almost 50% of patients experienced at least one side effect, which were mild in almost all cases, and similar between groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>CGRP mAbs were effective in approximately 1\/4 patients with treatment-refractory NDPH,but less likely to be effective in NDPH than CM. This suggests that NDPH cannot be seen as equivalent to CM and that new treatment options are required for this highly disabling disorder.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s10194-025-02111-2","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:49:45Z","timestamp":1753710585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Calcitonin gene-related peptide monoclonal antibody treatment for new daily persistent headache"],"prefix":"10.1186","volume":"26","author":[{"given":"Sanjay","family":"Cheema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija Rerhou","family":"Rantell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Lagrata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salwa","family":"Kamourieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjit","family":"Matharu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"22","key":"2111_CR1","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa1709038","journal-title":"N Engl J Med"},{"issue":"6","key":"2111_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"issue":"24","key":"2111_CR3","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211\u2013e2221. https:\/\/doi.org\/10.1212\/WNL.0000000000006640","journal-title":"Neurology"},{"issue":"13","key":"2111_CR4","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e1377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"issue":"1","key":"2111_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"issue":"5","key":"2111_CR6","doi-asserted-by":"publisher","first-page":"333102423116808","DOI":"10.1177\/03331024231168089","volume":"43","author":"S Cheema","year":"2023","unstructured":"Cheema S, Mehta D, Ray JC, Hutton EJ, Matharu MS (2023) New daily persistent headache: a systematic review and meta-analysis. Cephalalgia 43(5):3331024231168089. https:\/\/doi.org\/10.1177\/03331024231168089","journal-title":"Cephalalgia"},{"issue":"4\u20135","key":"2111_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/03331024211044440","volume":"42","author":"R Lobo","year":"2022","unstructured":"Lobo R, Wang M, Lobo S, Bahra A (2022) Time to retire \u2018new daily persistent headache\u2019: mode of onset of chronic migraine and tension-type headache. Cephalalgia 42(4\u20135):385\u2013395. https:\/\/doi.org\/10.1177\/03331024211044440","journal-title":"Cephalalgia"},{"key":"2111_CR8","doi-asserted-by":"publisher","unstructured":"Bancalari EM, Hernandez N, Soria A,\u00a0Bruera O\u00a0(2023) Case report: monoclonal antibodies as an alternative treatment for new daily persistent headache. Cephalalgia Rep 6.\u00a0https:\/\/doi.org\/10.1177\/25158163231195769","DOI":"10.1177\/25158163231195769"},{"key":"2111_CR9","doi-asserted-by":"publisher","first-page":"858709","DOI":"10.3389\/fpain.2022.858709","volume":"3","author":"E Ozkan","year":"2022","unstructured":"Ozkan E, Celebi O, Keskin O, Gursoy A, Gursoy-Ozdemir Y (2022) Is persistent post-COVID headache associated with protein-protein interactions between antibodies against viral spike protein and CGRP receptor?: A case report. Front Pain Res (Lausanne) 3:858709. https:\/\/doi.org\/10.3389\/fpain.2022.858709","journal-title":"Front Pain Res (Lausanne)"},{"key":"2111_CR10","unstructured":"National Institute for Health and Care Excellence (2021) Erenumab for preventing migraine. Technology appraisal guidance [TA682]. https:\/\/www.nice.org.uk\/guidance\/ta682. Accessed 4 Jan 2025"},{"key":"2111_CR11","unstructured":"National Institute for Health and Care Excellence (2022) Galcanezumab for preventing migraine. Technology appraisal guidance. Reference number: TA659. https:\/\/www.nice.org.uk\/guidance\/ta659. Accessed 4 Jan 2025"},{"issue":"1","key":"2111_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/head.14051","volume":"61","author":"S Saely","year":"2021","unstructured":"Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C (2021) Hypertension: a new safety risk for patients treated with erenumab. Headache 61(1):202\u2013208. https:\/\/doi.org\/10.1111\/head.14051","journal-title":"Headache"},{"issue":"8","key":"2111_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/a:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12(8):963\u2013974. https:\/\/doi.org\/10.1023\/a:1026119331193","journal-title":"Qual Life Res"},{"issue":"6","key":"2111_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361\u2013370. https:\/\/doi.org\/10.1111\/j.1600-0447.1983.tb09716.x","journal-title":"Acta Psychiatr Scand"},{"issue":"10","key":"2111_CR15","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"issue":"2","key":"2111_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/MLR.0b013e3181c1328f","volume":"48","author":"MD Spreeuwenberg","year":"2010","unstructured":"Spreeuwenberg MD, Bartak A, Croon MA, Hagenaars JA, Busschbach JJ, Andrea H et al (2010) The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health. Med Care 48(2):166\u2013174. https:\/\/doi.org\/10.1097\/MLR.0b013e3181c1328f","journal-title":"Med Care"},{"issue":"4","key":"2111_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1037\/1082-989X.9.4.403","volume":"9","author":"DF McCaffrey","year":"2004","unstructured":"McCaffrey DF, Ridgeway G, Morral AR (2004) Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods 9(4):403\u2013425. https:\/\/doi.org\/10.1037\/1082-989X.9.4.403","journal-title":"Psychol Methods"},{"key":"2111_CR18","unstructured":"Ridgeway G, McCaffrey D, Morral A, Griffin BA (2013) TWANG: Toolkit for Weighting and Analysis of Nonequivalent Groups. http:\/\/CRAN.R-project.org\/package=twang. Accessed 21 Aug 2024"},{"issue":"2","key":"2111_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S et al (2022) Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 42(2):108\u2013118. https:\/\/doi.org\/10.1177\/03331024211053571","journal-title":"Cephalalgia"},{"issue":"1","key":"2111_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s10194-020-01136-z","volume":"21","author":"H Ashina","year":"2020","unstructured":"Ashina H, Iljazi A, Al-Khazali HM, Eigenbrodt AK, Larsen EL, Andersen AM et al (2020) Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study. J Headache Pain 21(1):62. https:\/\/doi.org\/10.1186\/s10194-020-01136-z","journal-title":"J Headache Pain"},{"issue":"1","key":"2111_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/head.14026","volume":"61","author":"A Yiangou","year":"2021","unstructured":"Yiangou A, Mitchell JL, Fisher C, Edwards J, Vijay V, Alimajstorovic Z et al (2021) Erenumab for headaches in idiopathic intracranial hypertension: a prospective open-label evaluation. Headache 61(1):157\u2013169. https:\/\/doi.org\/10.1111\/head.14026","journal-title":"Headache"},{"issue":"1","key":"2111_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s10194-022-01456-2","volume":"23","author":"M Lowe","year":"2022","unstructured":"Lowe M, Murray L, Tyagi A, Gorrie G, Miller S, Dani K et al (2022) Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation. J Headache Pain 23(1):86. https:\/\/doi.org\/10.1186\/s10194-022-01456-2","journal-title":"J Headache Pain"},{"key":"2111_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pediatrneurol.2020.09.014","volume":"114","author":"KA Greene","year":"2021","unstructured":"Greene KA, Gentile CP, Szperka CL, Yonker M, Gelfand AA, Grimes B et al (2021) Calcitonin gene-related peptide monoclonal antibody use for the preventive treatment of refractory headache disorders in adolescents. Pediatr Neurol 114:62\u201367. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2020.09.014","journal-title":"Pediatr Neurol"},{"issue":"6","key":"2111_CR24","doi-asserted-by":"publisher","first-page":"333102423118212","DOI":"10.1177\/03331024231182126","volume":"43","author":"A Buture","year":"2023","unstructured":"Buture A, Tomkins EM, Shukralla A, Troy E, Conaty K, Macken E et al (2023) Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: new daily persistent headache or persistent post-traumatic headache in the majority of cases. Cephalalgia 43(6):3331024231182126. https:\/\/doi.org\/10.1177\/03331024231182126","journal-title":"Cephalalgia"},{"issue":"5","key":"2111_CR25","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2018) Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38(5):815\u2013832. https:\/\/doi.org\/10.1177\/0333102418758283","journal-title":"Cephalalgia"},{"issue":"12","key":"2111_CR26","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/jnnp-2020-324674","volume":"92","author":"JC Ray","year":"2021","unstructured":"Ray JC, Kapoor M, Stark RJ, Wang SJ, Bendtsen L, Matharu M et al (2021) Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects. J Neurol Neurosurg Psychiatry 92(12):1325\u20131334. https:\/\/doi.org\/10.1136\/jnnp-2020-324674","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"2111_CR27","doi-asserted-by":"publisher","first-page":"333102425131744","DOI":"10.1177\/03331024251317448","volume":"45","author":"S Cheema","year":"2025","unstructured":"Cheema S, Lagrata S, Rantell KR, Ahmed M, Kamourieh S, Matharu MS (2025) OnabotulinumtoxinA for primary new daily persistent headache and comparison to chronic migraine. Cephalalgia 45(2):3331024251317448. https:\/\/doi.org\/10.1177\/03331024251317448","journal-title":"Cephalalgia"},{"issue":"7","key":"2111_CR28","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/head.13849","volume":"60","author":"R Burstein","year":"2020","unstructured":"Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF (2020) Mechanism of action of onabotulinumtoxinA in chronic migraine: a narrative review. Headache 60(7):1259\u20131272. https:\/\/doi.org\/10.1111\/head.13849","journal-title":"Headache"},{"issue":"11","key":"2111_CR29","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1177\/0333102414527648","volume":"34","author":"R Burstein","year":"2014","unstructured":"Burstein R, Zhang X, Levy D, Aoki KR, Brin MF (2014) Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia 34(11):853\u2013869. https:\/\/doi.org\/10.1177\/0333102414527648","journal-title":"Cephalalgia"},{"issue":"44","key":"2111_CR30","doi-asserted-by":"publisher","first-page":"10587","DOI":"10.1523\/JNEUROSCI.2211-17.2017","volume":"37","author":"A Melo-Carrillo","year":"2017","unstructured":"Melo-Carrillo A, Strassman AM, Nir RR, Schain AJ, Noseda R, Stratton J et al (2017) Fremanezumab-A humanized monoclonal anti-CGRP antibody-inhibits thinly myelinated (Adelta) but not unmyelinated (C) meningeal nociceptors. J Neurosci 37(44):10587\u201310596. https:\/\/doi.org\/10.1523\/JNEUROSCI.2211-17.2017","journal-title":"J Neurosci"},{"issue":"1","key":"2111_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s10194-023-01639-5","volume":"24","author":"S Cheema","year":"2023","unstructured":"Cheema S, Stubberud A, Rantell K, Nachev P, Tronvik E, Matharu M (2023) Phenotype of new daily persistent headache: subtypes and comparison to transformed chronic daily headache. J Headache Pain 24(1):109. https:\/\/doi.org\/10.1186\/s10194-023-01639-5","journal-title":"J Headache Pain"},{"issue":"22","key":"2111_CR32","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"issue":"1","key":"2111_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61. https:\/\/doi.org\/10.1186\/s10194-020-01127-0","journal-title":"J Headache Pain"},{"issue":"13","key":"2111_CR34","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R (2020) Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 40(13):1511\u20131522. https:\/\/doi.org\/10.1177\/0333102420946725","journal-title":"Cephalalgia"},{"issue":"5","key":"2111_CR35","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00415-023-12103-4","volume":"271","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Aurilia C, Egeo G, Proietti S, D\u2019Onofrio F, Torelli P et al (2024) Ultra-late response (>\u200924 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. J Neurol 271(5):2434\u20132443. https:\/\/doi.org\/10.1007\/s00415-023-12103-4","journal-title":"J Neurol"},{"issue":"11","key":"2111_CR36","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/j.1468-2982.2009.01842.x","volume":"29","author":"RB Grande","year":"2009","unstructured":"Grande RB, Aaseth K, Lundqvist C, Russell MB (2009) Prevalence of new daily persistent headache in the general population. The Akershus study of chronic headache. Cephalalgia 29(11):1149\u20131155. https:\/\/doi.org\/10.1111\/j.1468-2982.2009.01842.x","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02111-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02111-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02111-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T22:05:20Z","timestamp":1753913120000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02111-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2111"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02111-2","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research ethics committee approval was obtained from the London \u2013 Chelsea Research Ethics Committee, reference number 21\/PR\/0827. All patients gave informed consent to receive CGRP monoclonal antibody treatment and for their anonymised data to be collected for research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants gave informed consent for their anonymised data to be collected for research. No personally identifiable information is contained within the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SC and KR report no disclosures relevant to the manuscript. RP has received payment for the delivery of educational material from TEVA. SL has received payment for the development and delivery of educational material from AbbVie, Lundbeck, TEVA, Tillotts Pharma, Organon and sat on an advisory board for Abbvie, Lundbeck and TEVA. SK has received payment for the development and delivery of educational material from AbbVie and sat on an advisory board for Lundbeck. MM is chair of the medical advisory board of the CSF Leak Association; has served on advisory boards for Allergan, Autonomic Technologies Inc, Eli Lilly, Novartis, Pfizer, Salvia and TEVA; has received payment for educational presentations from Allergan, electroCore, Eli Lilly, Novartis and TEVA; has received grants from Abbott, Medtronic and electroCore; and has a patent on system and method for diagnosing and treating headaches (WO2018051103A1, issued).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}